{
  "drug_name": "Plenvu",
  "set_id": "79f930fa-5674-4f30-8ae8-9448d6243797",
  "source": "DailyMed",
  "sections": {
    "indications_and_usage": {
      "title": "1 INDICATIONS AND USAGE ",
      "content": "PLENVU ® is indicated for cleansing of the colon in preparation for colonoscopy in adults."
    },
    "dosage_and_administration": {
      "title": "2 DOSAGE AND ADMINISTRATION ",
      "content": "Preparation and Administration: • Two doses of PLENVU are required for a complete preparation for colonoscopy, using a “Two-Day” or “One-Day” dosage regimen. ( 2.1 ) • Reconstitute PLENVU in water prior to ingestion. ( 2.1 ) • Consume additional clear liquids after each dose of PLENVU in both dosing regimens. ( 2.1 , 5.1 ) • Administer oral medications at least 1 hour before starting each dose of PLENVU. ( 2.1 , 7.2 ) Recommended Dosage Regimens: • Two-Day Split Dosage : Dose 1 the evening before the colonoscopy (approximately 4 pm to 8 pm) and Dose 2 the next morning (approximately12 hours after the start of Dose 1). ( 2.1 , 2.2 ) • One-Day Morning Dosage : Dose 1 the morning of the colonoscopy (approximately 3 am to 7 am) and Dose 2 a minimum of 2 hours after the start of Dose 1. ( 2.1 , 2.3 ) • For complete information on dosing, preparation and administration, see full prescribing information. ( 2.1 , 2.2 , 2.3 )"
    },
    "special_populations": {
      "title": "8.6 Renal Impairment ",
      "content": "Use PLENVU with caution in patients with renal impairment or patients taking concomitant medications that may affect renal function [see Drug Interactions ( 7.1 )] . These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of PLENVU, and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Warnings and Precautions ( 5.4 )] ."
    },
    "contraindications": {
      "title": "4 CONTRAINDICATIONS ",
      "content": "PLENVU is contraindicated in the following conditions: • Gastrointestinal (GI) obstruction [see Warnings and Precautions ( 5.6 )] • Bowel perforation [see Warnings and Precautions ( 5.6 )] • Gastric retention • Ileus • Toxic megacolon • Hypersensitivity to any ingredient in PLENVU [see Warnings and Precautions ( 5.10 )]"
    },
    "warnings": {
      "title": "5 WARNINGS AND PRECAUTIONS ",
      "content": "• Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. ( 5.1 , 5.2 , 7.1 ) • Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. ( 5.2 ) • Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizure, including medications that lower the seizure threshold. ( 5.3 , 7.1 ) • Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider testing. ( 5.4 , 7.1 , 8.6 ) • Mucosal ulcerations : Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. ( 5.5 ) • Suspected GI obstruction or perforation : Rule out diagnosis before administration. ( 4 , 5.6 ) • Patients at risk for aspiration : Observe during administration. ( 5.7 ) • Glucose-6-phosphate dehydrogenase deficiency (G6PD): Use with caution. ( 5.8 ) • Risks in patients with phenylketonuria : Contains phenylalanine. ( 5.9 ) • Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur. ( 5.10 )"
    },
    "adverse_reactions": {
      "title": "6 ADVERSE REACTIONS ",
      "content": "The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: • Serious Fluid and Electrolyte Abnormalities [see Warnings and Precautions ( 5.1 )] • Cardiac Arrhythmias [see Warnings and Precautions ( 5.2 )] • Seizures [see Warnings and Precautions ( 5.3 )] • Patients with Renal Impairment [see Warnings and Precautions ( 5.4 )] • Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis [see Warnings and Precautions ( 5.5 )] • Patients with Significant Gastrointestinal Disease [see Warnings and Precautions ( 5.6 )] • Aspiration [see Warnings and Precautions ( 5.7 )] • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency [see Warnings and Precautions ( 5.8 )] • Risks in Patients with Phenylketonuria [see Warnings and Precautions ( 5.9 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.10 )]"
    },
    "drug_interactions": {
      "title": "7 DRUG INTERACTIONS ",
      "content": "Drugs that increase risks due to fluid and electrolyte changes. ( 7.1 )"
    },
    "patient_counseling_information": {
      "title": "17 PATIENT COUNSELING INFORMATION ",
      "content": "Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Instruct patients: • Two doses of PLENVU are required for a complete preparation for colonoscopy either as a Two-Day Split Dosage or One-Day Morning Dosage regimen [see Instructions for Use]. • Follow the directions in the Instructions for Use , for either the Two-Day Split Dosage or the One-Day Morning Dosage regimen, as prescribed. • Reconstitute each pouch of PLENVU in the mixing container with water before ingestion and drink additional clear liquids. Examples of clear liquids can be found in the Instructions for Use. Do not reconstitute with other liquids and/or add starch-based thickeners to the mixing container [see Warnings and Precautions (5.7)]. • Consume additional clear liquids before, during, and after the use of PLENVU to prevent dehydration [see Warnings and Precautions (5.1)] . • Consume only clear liquids (no solid food) from the start of PLENVU treatment until after the colonoscopy. • Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material. • Do not take other laxatives while taking PLENVU. • PLENVU contains 491 mg of phenylalanine per treatment [see Warnings and Precautions (5.9)] . • Administer oral medications at least 1 hour before starting each dose of PLENVU. • Contact their healthcare provider if they develop significant vomiting or signs of dehydration after taking PLENVU or if they experience altered consciousness or seizures [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)]. • Stop drinking PLENVU temporarily or drink each portion at longer intervals if severe abdominal discomfort or distention develops until these symptoms diminish. If severe symptoms persist, contact their healthcare provider. Distributed by: Salix Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA Manufactured by: Norgine Limited 7 Tir-y-berth Industrial Estate New Road, Tir-y-berth Hengoed, CF82 8SJ United Kingdom (GBR) Patented. See https://patents.salix.com for US patent information. PLENVU is a registered trademark of the Norgine group of companies used under license. © 2023 Salix Pharmaceuticals, Inc. or its affiliates 9643003"
    }
  }
}